CEACAM16-AS1: A Potential Drug Target and Biomarker for Cardiovascular Disease

Target Name: CEACAM16-AS1

NCBI ID: G107985305

CEACAM16-AS1

Other Name(s): CEACAM16, CEACAM19 and PVR antisense RNA 1 | CEACAM16-AS1 variant X1 | CEACAM16, CEACAM19 and PVR antisense RNA 1, transcript variant X1

CEACAM16-AS1: A Potential Drug Target and Biomarker for Cardiovascular Disease

Abstract:

CEACAM16-AS1, a highly conserved non-coding RNA molecule, has been identified as a potential drug target and biomarker for cardiovascular disease. Its expression has been associated with various cardiovascular risk factors, including cardiovascular disease, hypertension, and diabetes. This article summarizes the current research on CEACAM16-AS1, its potential drug targets, and its role as a biomarker for cardiovascular disease.

Introduction:

Cardiovascular disease is a leading cause of morbidity and mortality worldwide, placing a significant burden on public health systems. The identification of potential drug targets and biomarkers for cardiovascular disease has the potential to improve diagnostic accuracy, treatment outcomes, and patient management. CEACAM16-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for cardiovascular disease due to its association with various cardiovascular risk factors.

Current Research on CEACAM16-AS1:

CEACAM16-AS1 has been shown to play a critical role in various cellular processes, including cell adhesion, migration, and invasion. It is a highly conserved non-coding RNA molecule that has been shown to have similar sequence and structure to other non-coding RNAs, such as microRNA (miRNA) and long non-coding RNA (lncRNA). CEACAM16-AS1 has been shown to regulate the expression of various genes, including those involved in cardiovascular disease risk factors, such as the angiogenesis, hypertension, and diabetes.

CEACAM16-AS1 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. The TGF-β pathway is a well-established regulator of cell growth, differentiation, and survival, and has been implicated in various diseases, including cardiovascular disease. CEACAM16-AS1 has been shown to play a role in the regulation of TGF-β signaling by binding to the TGF-β receptor and regulating the activity of the transcription factor, Smad.

Drug Targets for CEACAM16-AS1:

The identification of potential drug targets for CEACAM16-AS1 has the potential to improve the treatment outcomes for cardiovascular disease. Several potential drug targets have been identified for CEACAM16-AS1, including the TGF-β pathway, the Wnt signaling pathway, and theNotch signaling pathway.

The TGF-β pathway is a well-established regulator of cell growth, differentiation, and survival, and has been implicated in various diseases, including cardiovascular disease. CEACAM16-AS1 has been shown to play a role in the regulation of TGF-β signaling by binding to the TGF-β receptor and regulating the activity of the transcription factor, Smad. Therefore, targeting the TGF-β pathway could be a potential drug target for CEACAM16-AS1.

The Wnt signaling pathway is a critical regulator of cell growth and development, and has been implicated in various diseases, including cardiovascular disease. CEACAM16-AS1 has been shown to play a role in the regulation of Wnt signaling by binding to the Wnt receptor and regulating the activity of the transcription factor, FGF1. Therefore, targeting the Wnt signaling pathway could be a potential drug target for CEACAM16-AS1.

The Notch signaling pathway is a critical regulator of cell growth and development, and has been implicated in various diseases, including cardiovascular disease. CEACAM16-AS1 has been shown to play a role in the regulation of Notch signaling by binding to the Notch receptor and regulating the activity of the transcription factor, JAG1. Therefore, targeting the Notch signaling pathway could be a potential drug target for CEACAM16-AS1.

Biomarkers for CEACAM16-AS1:

CEACAM16-AS1 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway, the Wnt signaling pathway, and theNot

Protein Name: CEACAM16, CEACAM19 And PVR Antisense RNA 1

The "CEACAM16-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM16-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets